Close

Ratings by Guggenheim (Seamus Fernandez)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
9/21/2022 Bristol-Myers Squibb Co. BMY Maintain Buy
(N/A)
 
 
  Details
9/15/2022 Altimmune ALT Maintain Buy
(N/A)
 
 
  Details
9/8/2022 Albireo Pharma ALBO New Coverage Buy
(N/A)
16.67
(18.73)
12.36% Details
8/15/2022 Altimmune ALT Maintain Buy
(N/A)
 
 
  Details
5/24/2022 HilleVax, Inc. HLVX New Coverage Buy
(N/A)
9.50
(17.11)
80.11% Details
12/15/2021 Adagio ADGI Downgrade Neutral
(Buy)
7.26
(4.64)
-36.09% Details
12/7/2021 Merck MRK Downgrade Neutral
(Buy)
73.42
(86.78)
18.2% Details
9/21/2021 Eli Lilly LLY Maintain Buy
(N/A)
 
 
  Details
9/20/2021 Bristol-Myers Squibb Co. BMY Maintain Buy
(N/A)
 
 
  Details
8/31/2021 Adagio ADGI New Coverage Buy
(N/A)
30.38
(4.64)
-84.73% Details
4/26/2021 CureVac CVAC New Coverage Neutral
(N/A)
116.37
(7.48)
-93.57% Details
4/13/2021 Zai Lab ZLAB Maintain Buy
(N/A)
 
 
  Details
2/11/2021 Altimmune ALT New Coverage Buy
(N/A)
21.58
(12.37)
-42.68% Details
2/8/2021 Viela Bio VIE Downgrade Neutral
(Buy)
52.85
(53.01)
0.3% Details
10/19/2020 Bristol-Myers Squibb Co. BMY Upgrade Buy
(Neutral)
61.24
(70.71)
15.46% Details
8/24/2020 Merck MRK Maintain Buy
(N/A)
 
 
  Details
8/24/2020 Eli Lilly LLY Maintain Buy
(N/A)
 
 
  Details
8/12/2020 Arcutis Biotherapeutics Inc. ARQT Maintain Buy
(N/A)
 
 
  Details
6/16/2020 Eli Lilly LLY Upgrade Buy
(Neutral)
141.52
(311.46)
120.08% Details
4/15/2020 Zai Lab ZLAB New Coverage Buy
(N/A)
59.60
(37.00)
-37.92% Details
2/27/2020 Revance Therapeutic RVNC Maintain Buy
(N/A)
 
 
  Details
2/25/2020 Arcutis Biotherapeutics Inc. ARQT New Coverage Buy
(N/A)
27.05
(18.19)
-32.75% Details
2/11/2020 Viela Bio VIE Maintain Buy
(N/A)
 
 
  Details
2/3/2020 Dermira DERM Downgrade Neutral
(Buy)
18.95
(2.79)
-85.28% Details
1/7/2020 Viela Bio VIE Maintain Buy
(N/A)
 
 
  Details
1/6/2020 Merck MRK Maintain Buy
(N/A)
 
 
  Details
11/15/2019 Merck MRK Maintain Buy
(N/A)
 
 
  Details
10/28/2019 Viela Bio VIE New Coverage Buy
(N/A)
19.65
(53.01)
169.77% Details
8/7/2019 Allergen AGN Downgrade Neutral
(Buy)
159.49
(193.02)
21.02% Details
4/11/2019 Eli Lilly LLY Downgrade Neutral
(Buy)
127.24
(141.52)
11.22% Details
3/21/2019 Dermira DERM Maintain Buy
(N/A)
 
 
  Details
3/11/2019 Allergen AGN Maintain Buy
(N/A)
 
 
  Details
1/30/2019 Allergen AGN Maintain Buy
(N/A)
 
 
  Details
1/28/2019 Allergen AGN Maintain Buy
(N/A)
 
 
  Details
1/4/2019 Celgene CELG Downgrade Neutral
(Buy)
66.64
(108.24)
62.42% Details
11/27/2018 Bristol-Myers Squibb Co. BMY Maintain Neutral
(N/A)
 
 
  Details
11/20/2018 Dermira DERM New Coverage Buy
(Neutral)
9.71
(18.95)
95.16% Details
11/16/2018 Revance Therapeutic RVNC New Coverage Buy
(Neutral)
20.85
(25.02)
20% Details
10/9/2018 Allergen AGN New Coverage Buy
(Neutral)
190.17
(159.49)
-16.13% Details
10/9/2018 Bristol-Myers Squibb Co. BMY New Coverage Neutral
(Buy)
62.41
(70.71)
13.3% Details
10/9/2018 Merck MRK New Coverage Buy
(N/A)
71.03
(86.78)
22.17% Details
10/9/2018 Eli Lilly LLY New Coverage Buy
(N/A)
115.02
(127.24)
10.62% Details